ZIM Laboratories Limited Announces Q4 & FY26 Earnings Conference Call on 20th May 2026
ZIM Laboratories Limited has announced its Q4 & FY26 Earnings Conference Call, scheduled for Wednesday, 20th May 2026 at 12:00 PM IST, hosted by Go India Advisors. Senior management, including the Chairman and Managing Director and Chief Financial Officer, will participate in the call. Participants can pre-register via the Diamond Pass option or dial in using the universal numbers 086 3416 8787 & 086 4536 6906, with a recommendation to connect at least 5–10 minutes before the scheduled time.
*this image is generated using AI for illustrative purposes only.
ZIM Laboratories Limited has announced the scheduling of its Q4 & FY26 Earnings Conference Call, pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The call is set to take place on Wednesday, 20th May 2026, at 12:00 PM IST, and will be hosted by Go India Advisors. The intimation was filed with both BSE Limited and the National Stock Exchange of India Limited on 13th May 2026.
Key Details of the Earnings Conference Call
The following table summarises the essential details of the scheduled earnings call:
| Parameter: | Details |
|---|---|
| Event: | Q4 & FY26 Earnings Conference Call |
| Date: | Wednesday, 20th May 2026 |
| Time: | 12:00 PM IST |
| Hosted By: | Go India Advisors |
| Universal Dial-In Numbers: | 086 3416 8787 & 086 4536 6906 |
| Registration: | Diamond Pass pre-registration available |
Company Participants
The earnings call will feature participation from ZIM Laboratories' senior management team. The following key personnel are scheduled to be present:
- Dr. Anwar Siraj Daud — Chairman and Managing Director
- Mr. Zulfiqar Kamal — Director (Finance)
- Mr. Shyam Mohan Patro — Chief Financial Officer
- Mr. Zain Daud — Investor Relations
Dial-In and Registration Information
Participants are advised to dial in at least 5–10 minutes prior to the scheduled start time to ensure timely connectivity. Pre-registration via the Diamond Pass option is available to help avoid wait times. For further information, investors and analysts may contact Go India Advisors through Deepika Sharma at deepika@goindiaadvisors.com or Sheetal Khanduja at sheetal@goindiaadvisors.com .
The intimation was submitted by Piyush Nikhade, Company Secretary and Compliance Officer (Membership No. A38972), on behalf of ZIM Laboratories Limited.
Historical Stock Returns for Zim Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.76% | -5.56% | +27.77% | +31.65% | +5.85% | -13.13% |
What revenue growth trajectory and margin expansion can investors expect ZIM Laboratories to report for FY26 given the competitive pharmaceutical landscape in India?
How might ZIM Laboratories' pipeline of novel drug delivery technologies influence its guidance and capital allocation strategy for FY27?
Will management provide clarity on any pending regulatory approvals or international market expansions that could serve as key growth catalysts in the near term?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
